Stay updated with breaking news from Caredx Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CareDx is the exclusive licensee of U.S. Patents 8,703,652, 9,845,497, and 10,329,607 entitled "Non-Invasive Diagnosis of Graft Rejection in Organ Transplant Patients" owned by Stanford.
Baron Funds, an investment management company, released its “Baron Discovery Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
BRISBANE, Calif. (AP) — BRISBANE, Calif. (AP) — CareDx Inc. (CDNA) on Monday reported a loss of $18.3 million in its fourth quarter. The Brisbane, California-based company said it had a loss of 34 cents per share.
/PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that...
In Monster Energy Co. v. Vital Pharmaceuticals, Bang Energy, the core focus of the dispute was on whether creatine was the same as super creatine Bang claims to use in their energy drinks and whether the latter afforded the benefits touted in the advertising campaigns by Bang.